EN
登录

美敦力将收购Contego Medical,扩大下一代颈动脉治疗的可及性

Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies

美敦力 等信源发布 2026-11-16 19:50

可切换为仅中文


GALWAY, Ireland

爱尔兰,戈尔韦

,

,

Nov. 16, 2026

2026年11月16日

/

/

PRNewswire

美通社

/ -- Medtronic (NYSE: MDT), the global leader in healthcare technology, today announced its intent to acquire Contego Medical, a privately held medical device company focused on innovative solutions for carotid artery disease and peripheral thrombectomy.

/ -- 全球医疗技术领导者美敦力(纽约证券交易所代码:MDT)今日宣布,拟收购Contego Medical。这是一家私营医疗器械公司,专注于为颈动脉疾病和外周血栓切除术提供创新解决方案。

The acquisition will build on the company's successful, exclusive U.S. distribution agreement with Contego, first announced in January 2025, and advances the Medtronic strategy of pursuing targeted investments that strengthen the company's core franchises. The deal specifically expands the Medtronic portfolio of differentiated carotid technologies, broadening patient access to innovative therapies for carotid artery and peripheral vascular disease..

此次收购将建立在该公司与Contego于2025年1月首次宣布的成功的美国独家分销协议基础之上,并推进美敦力通过针对性投资来强化其核心业务板块的战略。该交易特别扩大了美敦力在差异化颈动脉技术领域的产品组合,使更多患者能够获得针对颈动脉疾病和外周血管疾病的创新疗法。

'With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,' said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company's Cardiovascular portfolio. 'By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data,.

“通过此次收购,美敦力在加强我们于颈动脉疾病治疗领域的领导地位方面又迈出了重要一步,”美敦力外周血管健康业务高级副总裁兼总裁David Moeller表示。该业务隶属于公司心血管产品组合。“通过将美敦力在外周和神经血管技术方面的深厚临床经验,与Contego凭借强劲且一致的临床数据支持的下一代治疗方案相结合,”

†

†

we intend to become an undisputed leader in carotid revascularization.'

我们旨在成为颈动脉血运重建领域无可争议的领导者。

Carotid artery disease occurs when the carotid arteries, the major blood vessels supplying the brain, become narrowed or blocked. Plaque can then rupture or embolize and lead to a stroke, accounting for about 20% of ischemic strokes.

颈动脉疾病发生在供应大脑的主要血管——颈动脉变得狭窄或阻塞时。斑块随后可能破裂或脱落形成栓子,从而导致卒中,约占缺血性卒中的20%。

1

1

While carotid revascularization is intended to reduce stroke risk, embolic debris released during treatment can contribute to procedural stroke risk.

尽管颈动脉血运重建旨在降低卒中风险,但治疗过程中释放的栓塞性碎片可能增加手术相关的卒中风险。

2-5

2-5

Contego Medical, founded by Ravish Sachar, MD, and Jay Yadav, MD, developed technology designed to address this challenge through integrated embolic protection.

由Ravish Sachar博士和Jay Yadav博士创立的Contego Medical公司,开发了旨在通过集成栓塞保护技术来应对这一挑战的技术。

'Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter,' said Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical.

“Contego 的成立旨在通过开发旨在改善治疗效果并同时简化手术流程的技术,来满足临床实践中尚未被满足的需求。深化与美敦力的合作是我们令人兴奋的崭新篇章。”Contego Medical 创始人兼首席执行官 Ravish Sachar 博士表示。

'We're proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients.'.

“我们为团队感到自豪,并感谢帮助将这些技术带给患者的医生、研究站点、员工和投资者。”

The planned acquisition includes Contego's recently FDA-approved Neuroguard IEP*™ Direct System, the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the prospective, multicenter PERFORMANCE III study,

此次计划中的收购包括 Contego 公司最近获得美国食品药品监督管理局(FDA)批准的 Neuroguard IEP*™ Direct 系统,这是首个也是唯一一个在血流逆转基础上集成栓塞防护功能的经颈动脉血运重建系统(TCAR-IEP)。在前瞻性、多中心的 PERFORMANCE III 研究中,

6

6

the Neuroguard IEP Direct System demonstrated exceptional outcomes at 30 days:

Neuroguard IEP Direct 系统在30天时展现出卓越的疗效:

Zero strokes

零笔划

6

6

Zero neurological deaths

零例神经性死亡

6

6

Zero cranial nerve injuries

无颅神经损伤

6

6

Zero myocardial infarctions

零例心肌梗死

6

6

'Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients,' said Linnea Burman, senior vice president and president of Medtronic Neurovascular.  'We are committed to delivering technologies designed to reduce stroke risk and advance patient care.

“卒中相关的残疾凸显了对更多创新治疗方案的迫切需求,也为改善患者预后提供了重要契机。”美敦力神经血管业务高级副总裁兼总裁Linnea Burman表示,“我们致力于提供旨在降低卒中风险并提升患者护理水平的技术。”

Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease.'.

我们计划收购 Contego,此举进一步彰显了我们的承诺,有助于医生为更多颈动脉疾病患者带来具有临床意义的创新。

Beyond carotid revascularization, the acquisition includes Contego's Excipio*™ thrombectomy devices, which complement Medtronic's Liberant™ thrombectomy system in the treatment of peripheral vascular disease.

除颈动脉血运重建业务外,此次收购还包括 Contego 的 Excipio*™ 血栓切除术器械,这些器械与美敦力的 Liberant™ 血栓切除系统相辅相成,用于外周血管疾病的治疗。

Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. Valued at $380 million with potential payments post-acquisition, the acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and FY28 and neutral to accretive thereafter..

美敦力预计将在其财政年度第三季度完成此次交易,具体取决于惯例交割条件。该收购交易价值为3.8亿美元,并包含潜在的收购后付款,预计在2027和2028财年将小幅摊薄美敦力的调整后每股收益,此后则为中性或增厚效应。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries.

大胆思考,更大胆行动。我们是美敦力。美敦力公司(Medtronic plc)总部位于爱尔兰戈尔韦,是全球领先的医疗科技公司,通过积极探索并寻找解决方案,勇敢应对人类面临的最严峻健康挑战。我们的使命——减轻病痛、恢复健康、延长寿命——凝聚了遍布150多个国家的9万余名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法涵盖70种健康状况,包括心脏设备、手术机器人、手术工具、患者监护系统等。凭借我们多元化的知识、永不满足的好奇心以及帮助所有需要帮助者的愿望,我们提供创新技术,每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们赋能以洞察为驱动的医疗护理、打造以人为本的体验,并为我们的世界带来更佳的成果,您将看到我们更多的作为。在我们所做的一切中,我们致力于缔造非凡。欲了解更多关于美敦力的信息,请访问。

www.Medtronic.com

www.Medtronic.com

and follow Medtronic on

并在以下平台关注美敦力

LinkedIn

领英

.

。

About Contego Medical, Inc.

关于 Contego Medical, Inc.

Contego Medical, Inc. is the leader in developing state-of-the-art solutions that transform complex cases into simplified procedures. The company's portfolio of integrated, multi-functional products is designed to improve patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease.

Contego Medical, Inc. 是开发尖端解决方案的领导者,致力于将复杂病例转化为简化手术。公司的集成化、多功能产品组合旨在改善颈动脉及外周血管疾病治疗中的患者预后和手术效率。

Contego's portfolio includes the Neuroguard IEP*™ System, the Neuroguard IEP*™ Direct System, and Excipio*™ Thrombectomy Device. Contego's growth and innovation have been supported by leading healthcare investors, including Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures, and Amzak Health..

Contego的产品组合包括Neuroguard IEP*™系统、Neuroguard IEP*™ Direct系统以及Excipio*™血栓切除装置。Contego的增长与创新得到了领先医疗保健投资者的支持,其中包括Hatteras Venture Partners、U.S. Venture Partners、Lightstone Ventures和Amzak Health。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受限于美敦力公司向美国证券交易委员会提交的定期报告中所描述的风险和不确定性。实际结果可能与预期结果存在重大差异。

Contacts:

联系人:

Justin Paquette

贾斯汀·帕凯特

Public Relations

公共关系

+1-612-271-7935

+1-612-271-7935

Ingrid Goldberg

英格丽德·戈德堡

Investor Relations

投资者关系

+1-763-505-2696

+1-763-505-2696

Footnotes

脚注

™*Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

™*第三方品牌为其各自所有者的商标。所有其他品牌均为美敦力公司的商标。

† First 3-in-1 carotid artery stenting system compared to standalone stents, balloons, and filters. Clinical outcomes claims are based on prospective, multicenter studies and registries evaluating Contego Medical technologies, including the PERFORMANCE I, PERFORMANCE II, PERFORMANCE III, and Paladin studies.

† 首个三合一颈动脉支架系统,相较于独立的支架、球囊和滤器。临床效果声明基于对Contego Medical技术进行评估的前瞻性、多中心研究和注册研究,包括PERFORMANCE I、PERFORMANCE II、PERFORMANCE III以及Paladin研究。

Individual study results may vary, and outcomes should not be directly compared across studies..

个体研究结果可能存在差异,不同研究之间的结果不应直接比较。

References

参考文献

Musialek P et al. Cardiovasc Res. 2023;121(1):13-43. doi:10.1093/cvr/cvad135

Musialek P 等. 《心血管研究》. 2023;121(1):13-43. doi:10.1093/cvr/cvad135

Antonius Carotid Endarterectomy, Angioplasty, and Stenting Study Group. Transcranial Doppler monitoring in angioplasty and stenting of the carotid bifurcation. J Endovasc Ther. 2003 Aug;10(4):702-710.

安东尼奥斯颈动脉内膜切除术、血管成形术和支架植入术研究组。经颅多普勒监测在颈动脉分叉处血管成形术和支架植入术中的应用。《血管内治疗杂志》. 2003年8月;10(4):702-710.

Martin JB, Pache JC, Treggiari-Venzi M, et al. Role of the distal balloon protection technique in the prevention of cerebral embolic events during carotid stent placement. Stroke. 2001 Feb;32(2):479-484.

Martin JB, Pache JC, Treggiari-Venzi M, 等. 远端球囊保护技术在颈动脉支架置入术中预防脑栓塞事件的作用. 《卒中》. 2001年2月;32(2):479-484.

Ackerstaff RG, Suttorp MJ, van den Berg JC, et al. Prediction of early cerebral outcome by transcranial Doppler monitoring in carotid bifurcation angioplasty and stenting. J Vasc Surg. 2005;41(4):618-624.

Ackerstaff RG, Suttorp MJ, van den Berg JC, 等. 经颅多普勒监测预测颈动脉分叉血管成形术及支架植入术的早期脑结局. 《血管外科杂志》. 2005;41(4):618-624.

Hellings WE, Ackerstaff RG, Pasterkamp G, De Vries JP, Moll FL. The carotid atherosclerotic plaque and microembolisation during carotid stenting. J Cardiovasc Surg (Torino). 2006 Apr;47(2):115-126.

Hellings WE,Ackerstaff RG,Pasterkamp G,De Vries JP,Moll FL。颈动脉支架植入术期间的颈动脉粥样硬化斑块与微栓塞。《心血管外科杂志》(都灵)。2006年4月;47(2):115-126。

Lyden SP, Mendes RR, Mouawad NJ, Mallios A, Mathews SJ, Pugar CE, et al; PERFORMANCE III Investigators. Thirty-day outcomes following transcarotid artery revascularization with integrated embolic protection: The PERFORMANCE III study. J Vasc Surg. 2026;84(4):951-960.e3. doi:10.1016/j.jvs.2026.05.027..

Lyden SP,Mendes RR,Mouawad NJ,Mallios A,Mathews SJ,Pugar CE 等;PERFORMANCE III 研究者。经颈动脉血运重建联合一体化栓塞保护的三十天结局:PERFORMANCE III 研究。《血管外科杂志》. 2026;84(4):951-960.e3. doi:10.1016/j.jvs.2026.05.027.

SOURCE Medtronic plc

来源:美敦力公司